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Non-invasive management
of organic impotence
F. J. L. Kaplan, N. S. Levitt, P. J. d'E. Stevens,
C. Phillips
Objective: To establish the efficacy of a vacuum device
(ErecAid) in the management of organic impotence.
Design: Cohort study; questionnaire before and after a
6-month study period.
Setting: Groote Schuur Hospital, Cape Town.
Participants: A total of 19 men with organic impotence,
8 diabetic and 11 with previous pelvic surgery or
radiotherapy
Intervention: Vacuum device (ErecAid, Osbon Medi_cal
Systems).
Outcome measure: Efficacy of ErecAid. .<
Results: Six of 8 diabetics and 6 of 11 non-diabetics
reported successful intercourse, while 16 of the
participants would recommend the device to others.
Some difficulty with the device was experienced by 11
and only 9 described an increase in self-esteem.
Conclusion: Although some difficulties may be
experienced in the use of the ErecAid, it clearly has a role
to play in the management of patients with organic
impotence, who ideally should be able to select their
preferred form of therapy.
S AfT Med J 1995; 85: 276-278.
Erectile dysfunction, most frequently psychogenic in nature,
is commonly encountered in clinical practice, affecting
approximately 10% of the adult male population.' However,
a number of conditions, including spinal cord injuries,
myelopathies and diabetes meliitus are associated with
organic impotence, with 35 - 50% of diabetic men being
affected!·3
Increased Willingness to report on sexual dysfunction, and
an ageing population seeking to maintain quality of life and
relationships, have resulted in considerable interest in the
treatment of impotence. Real advances have been made in
this area, including intracorporeal injections of papaverine
and prostaglandin E" and prosthetic surgery. These may,
however, be associated with problems such as long-term
penile fibrosis with intracorporeal injections: prolongation of
the effect of papaverine leading to priapism, and poor
response to prostaglandin E, in patients with disorders of
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the vascular system.' Explantation of 2 - 8,3% of penile
prostheses is necessary secondary to infection, erosion,
tissue necrosis or chronic pain.6
More recently, attention has turned toward reversible, non-
invasive external devices which simulate natural erections by
the use of vacuum suction and penile constriction.
Engorgement and rigidity result from placing the flaccid
penis in a custom-designed cylinder where inverse pressure
is applied, rapidly manipulating blood into the vascular
network of the penis; 50 - 70 ml of blood are necessary to
produce tumescence sufficient for intercourse.' External
tension is applied at the base of the organ to reduce venous
outflow once penile rigidity has been obtained. The cylinder
is then removed and the erection-like state is maintained
long enough to permit intercourse.
This study was undertaken to evaluate the efficacy of the
ErecAid (Osbon Medical Systems Ltd, Augusta, Georgia,
USA) (Fig. 1) in the management of organic impotence.
Fig. 1. The ErecAid constriction band-type vacuum device for the
treatment of impotence.
Subjects and methods
Nineteen men attending the Diabetic, Radiotherapy and
Stomatherapy Units of Groote Schuur Hospital took part in
the study. Diabetics with symptomatic erectile dysfunction,
absent nocturnal erections using the Dacomed Snap-Gauge
(Minneapolis, Minnesota), normal penile Doppler studies,
and normal testosterone and gonadotrophin concentrations
were included. Each couple was interviewed by an
experienced marital therapist who assessed the level of
functioning of the marital relationship and whether the wife
was interested in improving the relationship sexually. Eight
diabetics (mean age 52 years, range 39 - 69), 6 insulin-
dependent, and a further 11 patients (mean age 57,3 years,
range 40 - 69) with renal, bladder, rectal or prostatic disease
requiring surgery or radiotherapy, were included in the study.
The subjects had had failure of coitus in all attempts in the
previous 3 months, and the majority had not achieved
successful intercourse for 6 months - 10 years. Sixty-eight
per cent had received prior management for sexual
dysfunction, with no response in 77%. Papaverine and
counselling were most commonly used. The subjects rated
their sex drive at an average of 7/10 and their partners' at




Each couple attended a full private orientation and video
demonstration of the ErecAid device and had time to
discuss any problems openly. Two weeks later, the couples
were contacted telephonically to elucidate problems, while a
formal appointment was made 6 weeks after orientation. The
final assessment was made 6 months later.
Results
Successful intercourse with the ErecAid was reported by
63% of patients, 6 (75%) diabetics and 6 (55%) non-
diabetics. Of these, 54% reported successful intercourse at
least twice a week, 74% described their erections as 'firm'
or 'hard' and 58% the quality of orgasm as 'good' or
'excellent' .
A positive effect of the device on self-image was reported
in 47% of patients, while 21 % reported a negative effect.
The majority of participants (84%) would recommend the
device to others, Le. 88% of diabetics and 82% of non-
diabetics.
Fifty-eight per cent of patients encountered difficulties
with the use of the ErecAid, of whom 36% suffered pain,
64% discomfort, 21 % difficulty with the removal of the
device and 11 % discomfort with ejaculation.
Within 24 hours of receiving the device, 53% of patients
achieved proficiency in its use, while a further 37% were
successful by 5 days. Erection was achieved within 3
minutes by 79% of subjects. The patients' rating of the
device in the management of sexual dysfunction was 5/10,
6/10 in the diabetic group and 5/10 in the non-diabetic
group.
Discussion
In this study, although the sample size was small and the
majority had received previous treatment which was largely
unsuccessful, the ErecAid was beneficial in a considerable
proportion of patients, in agreement with previous studies.B•g
Notwithstanding the success rate with the ErecAid in this
study and the finding that the majority of participants would
recommend the device to others, fewer than 50% reported a
positive influence on their self-image, in contrast with
observations in previous studies"'!O Interestingly, the low
rating of the ErecAid among our participants, considering
the incidence of successful intercourse, appears to correlate
with the lack of effect on self-esteem. Possible explanations
for the low rating of the device include the unsatisfactory
quality of orgasm, discomfort with ejaculation, and the
relative coldness of the device experienced by a proportion
of the subjects.
Other problems which have been reported with the use of
the ErecAid include decreased skin temperature of the
penis, petechiae or ecchymoses of the penile skin, odour of
the device or lubricating jelly, problems with manual
dexterity and the necessity for precoital application of the
device.!O There is additionally the possibility of ischaemic
penile injury, particularly with prolonged use of external
vacuum devices, although the degree of decreased penile
bloodflow and the duration that may result in ischaemic
changes are not known.
--..._----------- SAMJ Volllme 85 No.4 April1995
In conclusion, in the management of erectile dysfunction,
it is important that patients be made aware of the various
options available to them, as well as their limitations,
specifically their inability to restore full sexual function. A full
prior assessment of the relationship between patients and
their partners combined with intermittent counselling during
the course of therapy might enhance the efficacy 'fIf the
therapeutic modality selected both in clinical trials and long-
term management.
We would like to thank Marcus Medical (Pty) Ltd (Cape Town)
for donating the ErecAid devices which have remained the
property of the patients.
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A lumbar body support
(KBS 2000) alters lumbar
muscle recruitment
patterns in patients with
acute-upon-chronic lower
back pain
K. L. Derman, E. w. Derman, T. D. Noakes
Objective. To determine the effects of a locally designed
lumbar body support (LBS) on integrated .
electromyographic (IEMG) activity of the lumbar erector
spinae muscles, on heart rate and on ratings of discomfort
in patients with low back pain. r
Design. Non-randomised controlled trial.
Setting. Patients referred from general practitioners and
back pain rehabilitation programmes in Cape Town.
Patients and other participants. Ten patients with low
back pain of diverse causes. Values were compared with
those in 1D control subjects without low back pain.
Intervention. Patients and controls lay supine on (in
random order) either a flat conventional mattress or a LBS
placed on top of the flat mattress, for a 3D-minute period
(acute exposure), and every night for 2 weeks (chronic
exposure).
Main outcome measures. IEMG activity ot the lumbar
erector spinae muscles, heart rate, and perception of
comfort.
Results. IEMG activity of the lumbar erector spinae
muscles did not differ between controls and patients when
lying on the LBS on top of the CM after either acute or
chronic exposure. However, it was significantly greater
(P < 0,05) in patients than in controls when lying on the flat
mattress. Subjective ratings of discomfort and heart rates
mirrored these changes and were higher in patients only
when lying on the flat mattress (P < 0,05). Patients with
low back pain also reported that sleeping overnight on the
LBS on top of their own mattress significantly reduced
discomfort ratings.
Conclusions. When lying on a mattress with a flat
surface, patients with chronic low back pain have higher
IEMG activity of the erector spinae muscles, higher heart
rates and higher subjective ratings of discomfort than do
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